Milk thistle Silybum marianum (L.) Gaertn.
Also called: Mary thistle, holy thistle, silymarin, Carduus marianus
Milk thistle is a tall, purple-flowered plant native to Europe and brought to North America by early colonists. Extracts are made from the seeds (fruit); their main constituent is silymarin, a mixture of compounds.
- Category
- Botanical
- Part used
- Seeds (fruit)
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-28
Class 1 Well studied in people. A 2007 Cochrane review included 18 randomized clinical trials (1,088 patients with alcoholic or hepatitis B or C liver disease) of milk thistle or its constituents versus placebo or no intervention. [3]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBlood sugar and weight1 topic
CPregnancy and infants1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Alcohol-related and hepatitis B or C liver disease | C | Cochrane (2007): 18 trials, 1,088 patients, mostly low quality; no significant effect on mortality, complications or histology; a liver-mortality signal vanished in high-quality trials. [3] |
| Hepatitis C and nonalcoholic steatohepatitis (NCCIH-funded trials) | X | Two NCCIH-funded studies of the extract silymarin, one in hepatitis C and one in nonalcoholic steatohepatitis, did not show benefits. [1] |
| Blood sugar in type 2 diabetes | C | A small number of studies, mostly from Middle Eastern countries, suggest extracts may help control blood sugar; generalizability is unclear. [1] |
| Breast milk production | C | NCCIH states the effect is unclear. [1] |
Main constituents: Silymarin, a group of flavanolignans, mainly silybinin, silychristin and silydianin [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Capsules or tablets contain silymarin in amounts of 250 to 750 mg, typically taken 2 to 3 times daily; total daily dose varies. [2]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score EABCDEA: well known causeE: unlikely cause
LiverTox likelihood score E: unlikely cause of clinically apparent liver injury (chapter last updated January 21, 2020).
Details and sources - Pregnancy and breastfeedingEU herbal monograph: safety during pregnancy and lactation has not been established …
2 statements in the profile.
Details and sources - Interactions with medicines7 listed
General (CYP450 enzymes and liver transporters); CYP3A4 substrates; UGT substrates; Sirolimus; Haloperidol or risperidone; Aripiprazole; Warfarin
Details and sources - Cancer evaluations (IARC, NTP)1 found
Each names the exact material tested, which may differ from a supplement.
Details and sources - FDA new dietary ingredient notifications1 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
EU herbal monograph, traditional use (EMA HMPC, adopted 5 June 2018), adults and elderly: herbal tea 3–5 g in 100 ml boiling water 2–3 times daily …
Details and sources
- Appears well tolerated orally; most common side effects are bloating, nausea and gas. [1]
- May cause allergic reactions, particularly in people allergic to related plants such as ragweed, chrysanthemum, marigold and daisy. [1]
- LiverTox likelihood score E (unlikely cause of clinically apparent liver injury). [2]
- Little is known about safety in pregnancy or breastfeeding. [1]
Interactions
| With | What happens |
|---|---|
| Drugs metabolized by CYP450 enzymes | Silymarin affects CYP450 enzymes and liver transporters in vitro, but there is little evidence of clinically significant herb-drug interactions. [2] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- Products in the US and elsewhere have been found with silymarin amounts substantially different from the label, or contaminated with pesticides, microorganisms or mycotoxins. [1]
Regulatory status
- US: herbal products for oral use are often marketed as dietary supplements, which, unlike drugs, are not approved by the FDA before sale; manufacturers are responsible for safety and labeling. [1]
- EU: an EU herbal monograph covers traditional use (long-standing use, not clinical trials) for digestive symptoms and to support liver function in adults, after serious conditions are excluded by a doctor. [4]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Silymarin, consisting largely of silybinin, silychristin and silydianin Flavanolignans (flavonolignans) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 1 entry naming Silybum marianum: NDI 1070 (submitted 2018-03-19), a combination of extracts of Silybum marianum, Trigonella foenum-graecum and Matricaria recutita. No entry names milk thistle, silymarin or silybin. Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P9]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- Milk thistle extract, 2-year feed studies (NTP TR-565, 2011): no evidence of carcinogenic activity in male or female F344/N rats or B6C3F1 mice at 12,500, 25,000 or 50,000 ppm. [P5]
- No IARC carcinogenicity evaluation of milk thistle or silymarin was found (IARC Monographs list of classifications checked 2026-10-29). [P10]
Liver (NIH LiverTox)
- LiverTox likelihood score E: unlikely cause of clinically apparent liver injury (chapter last updated January 21, 2020). [P1]
Interactions with medicines
- General (CYP450 enzymes and liver transporters): Silymarin affects cytochrome P450 enzymes and hepatic transporters in vitro, but there is little evidence that it causes clinically significant herb-drug interactions. [P1]
- CYP3A4 substrates: Milk thistle inhibits CYP3A4 and can affect concentrations of drugs it metabolizes, but conflicting data indicate no such effects; in one study milk thistle did not reduce indinavir levels. [P2]
- UGT substrates: Milk thistle modulates UGT enzymes in vitro and can increase the side effects of drugs metabolized by them. [P2]
- Sirolimus: Milk thistle may decrease sirolimus clearance. [P2]
- Haloperidol or risperidone: Seven cases of pancreatitis were reported following concomitant use with milk thistle. [P2]
- Aripiprazole: A case of hepatotoxicity was reported with combined use of milk thistle. [P2]
- Warfarin: Case report: a liver-cleanse supplement containing milk thistle was followed by an INR rise from 2.64 to 4.12 in a man on warfarin; INR normalized after stopping the supplement. [P2]
- Other medicinal products (EU monograph): The EU herbal monograph lists interactions as "None reported". [P4]
Alcohol
- MSK reports that silibinin can exacerbate the negative effects of chronic alcohol consumption on liver cancer; its mechanism discussion refers to reduced efficacy of silibinin in liver tumor-bearing animals co-administered ethanol. [P2]
Interactions with other herbs and supplements
- Garlic (with aspirin): Case report: severe epistaxis in a 25-year-old man, possibly due to self-medication with aspirin, garlic and milk thistle. [P2]
Adulteration and substitution
- BAPP Milk Thistle Extract adulteration bulletin (2020, by A. McCutcheon): describes the sale of depleted extracts, in which the silymarin has been reduced or removed without the buyer's knowledge, and details analytical methods to detect adulteration; results can differ partly because of HPLC-UV versus spectrophotometric methods. [P6]
- Products in the US and elsewhere have been found to contain silymarin amounts substantially different from the label, or to be contaminated with pesticides, microorganisms or mycotoxins. [P3]
- Raclariu-Manolică et al. 2023: of 18 milk thistle formulations, DNA metabarcoding detected milk thistle in 11 of 16 retained preparations, while metabolomics identified silymarin-complex molecules in all samples at different levels. [P7]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination of each component that is a dietary ingredient, before use — Required by 21 CFR 111.75(a)(1)(i); a manufacturer may petition for an exemption from this testing under 111.75(a)(1)(ii). [P11]
- Compliance with the Ph. Eur. milk thistle fruit monograph (ref. 1860) — The EU herbal monograph specifies that the material complies with Ph. Eur. monograph 1860. [P4]
- Silymarin (flavanolignan) assay, by HPLC-UV rather than spectrophotometry alone — Depleted extracts with silymarin reduced or removed are sold (BAPP 2020); HPLC-UV and spectrophotometric methods can give different results. [P6]
- Pesticide residues, microbial contamination and mycotoxins — Milk thistle products have been found contaminated with pesticides, microorganisms or mycotoxins. [P3]
- Combined chromatographic (UHPLC-MS) and DNA-based authentication — In a 2023 study, metabolomics and DNA metabarcoding gave complementary results on 18 commercial formulations. [P7]
Supply and conservation
- IUCN Red List: Least Concern (LC), via GBIF species API, retrieved 2026-10-29. [P12]
Absorption in people
- In 9 healthy volunteers given single oral doses of silymarin or a silybin-phosphatidylcholine complex (360 mg silybin equivalents), absorption was rapid and the terminal half-life of silybin was relatively short (generally less than 4 h) with either preparation. [P8]
- In a follow-up study in 9 healthy volunteers given the phosphatidylcholine complex (120 mg silybin equivalents twice daily for 8 days), plasma profiles on day 1 and day 8 were similar; the abstract reports that most circulating silybin was in conjugated form and that less than 3% of the dose was recovered in urine as free plus conjugated silybin, a significant proportion probably being excreted in bile. [P8]
Formulations studied to change absorption
Human data only.
- Silybin-phosphatidylcholine complex (IdB 1016) versus silymarin, single oral doses equivalent to 360 mg silybin in 9 healthy volunteers: plasma silybin levels were higher at all sampling times with the complex; the authors concluded complexation greatly increases the oral bioavailability of silybin. [P8]
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU herbal monograph, traditional use (EMA HMPC, adopted 5 June 2018), adults and elderly: herbal tea 3–5 g in 100 ml boiling water 2–3 times daily; powdered fruit 300–600 mg 2–3 times daily (up to 1,800 mg daily); dry extracts at stated single doses (e.g. ethanol 96% extract DER 30–40:1, 200 mg daily), before meals. Not recommended under 18 years. [P4]
Pregnancy and breastfeeding
Sources for this profile
- NIH LiverTox (NIDDK). Milk Thistle (Last Update: January 21, 2020), 2020-01-21. ncbi.nlm.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Milk Thistle (last updated July 22, 2026), 2026-07-22. mskcc.org
- NCCIH. Milk Thistle: Usefulness and Safety (Last Updated: 2025-02), 2025-02. nccih.nih.gov
- European Medicines Agency, HMPC. European Union herbal monograph on Silybum marianum (L.) Gaertn., fructus, EMA/HMPC/294187/2013 (final, adopted 5 June 2018), 2018-06-05. ema.europa.eu
- National Toxicology Program. TR-565: Toxicology and Carcinogenesis Studies of Milk Thistle Extract (CASRN 84604-20-6) in F344/N Rats and B6C3F1 Mice (Feed Studies) (2011), 2011. ntp.niehs.nih.gov
- American Botanical Council (press release). Milk Thistle Extract Adulteration Bulletin Released by Botanical Adulterants Prevention Program (October 19, 2020), 2020-10-19. globenewswire.com
- Raclariu-Manolică AC, et al. Authentication of milk thistle commercial products using UHPLC-QTOF-ESI+MS metabolomics and DNA metabarcoding. BMC Complement Med Ther 2023;23(1):257 (PMID 37480124), 2023-07-21. pubmed.ncbi.nlm.nih.gov
- Barzaghi N, et al. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990;15(4):333-8 (PMID 2088770), 1990-10. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (accessed October 29, 2026), 2026-10-29. monographs.iarc.who.int
- eCFR. 21 CFR 111.75 (title 21 displayed up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- GBIF species API: IUCN Red List category for Silybum marianum (L.) Gaertn., 2026-10-29. api.gbif.org
Sources
- NCCIH. Milk Thistle: Usefulness and Safety (Last Updated: 2025-02), 2025-02. nccih.nih.gov
- NIH LiverTox (NIDDK). Milk Thistle (Last Update: 2020-01-21), 2020-01-21. ncbi.nlm.nih.gov
- Cochrane Database of Systematic Reviews. Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. 2007;(4):CD003620 (PubMed abstract, PMID 17943794), 2007-10-17. pubmed.ncbi.nlm.nih.gov
- European Medicines Agency, HMPC. Silybi mariani fructus (milk thistle fruit) - herbal medicinal product, 2018-09-19. ema.europa.eu
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.